Summary
The aim of this 3-month double-blind study was to assess the antihypertensive effect and acceptability of perindopril in comparison with enalapril in patients with mild to moderate essential hypertension. After a 4-week placebo run-in period, 161 patients with supine diastolic blood pressure (DBP) between 95 and 115 mmHg were randomized to receive perindopril 4 mg or enalapril 10 mg once daily. If supine DBP was higher than 90 mmHg, treatment was adjusted monthly, first by doubling the dose and then by addition of hydrochlorothiazide 12.5 mg. After 3 months of active treatment the decrease in supine and standing blood pressures was statistically significant within both groups but was not statistically different between groups. The percentage of patients (65%) who achieved supine DBP of ≤90 mmHg in the perindopril group was not significantly different from the enalapril group (73%). Monotherapy resulted in control of supine DBP in 56% of the perindopril group and 58% of the enalapril group; the addition of hydrochlorothiazide resulted in control of supine DBP in 6% and 15% respectively. The number of withdrawals for adverse events was statistically significant between groups (0 in the perindopril group and 7 in the enalapril group, p=0.01). During active treatment the most frequently reported complaints were headaches and cough; there was not statistically difference between groups. Changes in laboratory parameters were minor and not significantly different between the two groups except for serum glucose, potassium, and triglyceride levels. In conclusion, there was no significance between perindopril and enalapril in terms of efficacy. Clinical acceptability seems to be better in the perindopril group. Therefore, perindopril may be recommended for the treatment of mild to moderate essential hypertension.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Williams GH. Converting enzyme inhibitors in the treatment of hypertension.N Engl J Med 1988;319:1517–1525.
The Fifth Report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. NIH publication, January 1993, No. 93–1088.
Lees KR, Green ST, Reid JL. Influence of age on the pharmakokinetics and pharmacodynamics of perindopril.Clin Pharmacol Ther 1988;44:418–425.
Bussien JP, D'Amore T, Perret L, et al. Single and repeated dosing of the converting enzyme inhibitor perindopril to normal subjects.Clin Pharmacol Ther 1986;39:554–558.
Lees KR, Reid JL. Haemodynamic and humoral effects of oral perindopril, an angiotensin converting enzyme inhibitor, in man.Br J Clin Pharmacol 1987;23:159–164.
Luccioni R, Frances Y, Gass R, Schwab C, Santoni JP, Perret L. Evaluation of the dose effect relationship of a new ACE inhibitor (perindopril) by an automatic blood pressure recorder.Eur Heart J 1988;9:1131–1136.
Chrysant SG, et al. Clinical efficacy and safety of perindopril erbumine: A dose-ranging comparison of two dosing regimens.Am J Hypertens 1991;4:27A.
Asmar RG, Pannier BM, Santoni JP, Safar ME. Angiotensin converting enzyme inhibition decreases systolic blood pressure more than diastolic pressure as shown by ambulatory blood pressure monitoring.J Hypertens 1988;6(Suppl 3):579–581.
West JNW, Smith SA, Stellerd TJ, Littler WA. Effects of perindopril on ambulatory intraarterial blood pressure, cardiovascular reflexes and forearm blood flow in essential hypertension.J Hypertens 1989;7:97–104.
Morgan T, Anderson A, Wilson D, Murphy J, Nowson C. The effect of perindopril on blood pressure in humans on different sodium intakes.J Cardiovasc Pharmacol 1987;10(Suppl 7):5116–5118.
Alcocer L, Exaire E, Herrera A. Results of the National Study on the treatment with enalapril in hypertensive patients.SP Inv Med Int 1988;14:273–280.
Bauer JH. Angiotensin converting enzyme inhibitors.Am J Hypertens 1990;3:331–337.
Lees K, Reid J, Scott M, Hosie J, Herpin D, Santoni JP. Captopril versus perindopril: A double-blind study in essential hypertension.J Hum Hypertens 1989;3:17–22.
Ajayi AA, Lees KR, Reid JL. Effects of angiotensin converting enzyme inhibitor, perindopril, on autonomic reflexes.Eur J Clin Pharmacol 1986;30:177–182.
Weinberger MH. Comparison of captopril and hydrochlorothiazide alone and in combination in mild to moderate essential hypertension.Br J Clin Pharmacol 1982;14(Suppl 2):127S-131S.
Husserl FE, Messerli FH. Adverse effects of antihypertensive drugs.Drugs 1981;22:188–210.
Degaute JP, Leeman M, Desche P. Long-term acceptability of perindopril: European multicenter trial on 856 patients.Am J Med 1992;92(Suppl 4B):845–905.
Yeo WW, Ramsay LE. Persistent dry cough with enalapril: Incidence depends on method used.J Hum Hypertens 1990;4:517–520.
Parra J, Alcocer L, Olvera S, et al. Multicentric study of quinapril, an angiotensin converting enzyme inhibitor, in the treatment of mild to moderate essential hypertension.Curr Ther Res 1992;51:185–195.
Oksa A, Gasdos M, Fedelesova V, Spustova V, Dzurik R. Effects of angiotensin-converting enzyme inhibitors on glucose and lipid metabolism in essential hypertension.J Cardiovasc Pharmacol 1994;23(1):79–86.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Alcocer, L., Campos, C., Bahena, J.H. et al. Clinical acceptability of ACE inhibitor therapy in mild to moderate hypertension, a comparison between perindopril and enalapril. Cardiovasc Drug Ther 9, 431–436 (1995). https://doi.org/10.1007/BF00879032
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00879032